INTENSITY THERAPEUTICS, INC. Operating Income
INTENSITY THERAPEUTICS, INC. (INTS) reported Operating Income of -$3.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-11
- INTENSITY THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-06-30 was -$3.08M.
- INTENSITY THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-03-31 was -$2.53M.
- INTENSITY THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-12-31 was -$3.14M.
- INTENSITY THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-09-30 was -$2.73M.
- INTENSITY THERAPEUTICS, INC. operating income (loss) for fiscal 2025 was -$11.97M.
- INTENSITY THERAPEUTICS, INC. operating income (loss) for fiscal 2024 was -$16.59M.
- INTENSITY THERAPEUTICS, INC. operating income (loss) for fiscal 2023 was -$8.32M.
- INTENSITY THERAPEUTICS, INC. operating income (loss) for fiscal 2022 was -$7.55M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$3.08M 10-Q · filed 2026-08-11 | -$5.61M 10-Q · filed 2026-08-11 | -$8.75M derived: sum of 3 quarters · filed 2026-08-11 | -$11.48M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2026-03-31 | -$2.53M 10-Q · filed 2026-05-07 | -$5.67M derived: sum of 2 quarters · filed 2026-05-07 | -$8.40M derived: sum of 3 quarters · filed 2026-05-07 | -$11.10M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-12-31 | -$3.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$5.87M derived: sum of 2 quarters · filed 2026-03-27 | -$8.58M derived: sum of 3 quarters · filed 2026-08-11 | -$11.97M 10-K · filed 2026-03-27 | |||
| 2025-09-30 | -$2.73M 10-Q · filed 2025-11-06 | -$5.44M derived: sum of 2 quarters · filed 2026-08-11 | -$8.83M 10-Q · filed 2025-11-06 | -$12.04M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-06-30 | -$2.71M 10-Q · filed 2026-08-11 | -$6.10M 10-Q · filed 2026-08-11 | -$9.30M derived: sum of 3 quarters · filed 2026-08-11 | -$12.87M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | -$3.39M 10-Q · filed 2026-05-07 | -$6.60M derived: sum of 2 quarters · filed 2026-05-07 | -$10.17M derived: sum of 3 quarters · filed 2026-05-07 | -$15.24M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | -$3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$6.77M derived: sum of 2 quarters · filed 2026-03-27 | -$11.84M derived: sum of 3 quarters · filed 2026-03-27 | -$16.59M 10-K · filed 2026-03-27 | |||
| 2024-09-30 | -$3.57M 10-Q · filed 2025-11-06 | -$8.64M derived: sum of 2 quarters · filed 2025-11-06 | -$13.38M 10-Q · filed 2025-11-06 | -$16.73M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2024-06-30 | -$5.07M 10-Q · filed 2025-08-07 | -$9.81M 10-Q · filed 2025-08-07 | -$13.16M derived: sum of 3 quarters · filed 2025-08-07 | -$15.65M derived: sum of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | -$4.74M 10-Q · filed 2025-05-13 | -$8.10M derived: sum of 2 quarters · filed 2025-05-13 | -$10.59M derived: sum of 3 quarters · filed 2025-05-13 | -$11.81M derived: sum of 4 quarters · filed 2025-05-13 | |||
| 2023-12-31 | -$3.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$5.84M derived: sum of 2 quarters · filed 2025-03-13 | -$7.06M derived: sum of 3 quarters · filed 2025-03-13 | -$8.32M 10-K · filed 2025-03-13 | |||
| 2023-09-30 | -$2.49M 10-Q · filed 2024-11-13 | -$2.49M 10-Q · filed 2023-11-13 | -$3.71M derived: sum of 2 quarters · filed 2024-11-13 | -$4.97M 10-Q · filed 2024-11-13 | -$4.97M 10-Q · filed 2023-11-13 | -$6.44M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | -$1.22M 10-Q · filed 2024-08-08 | -$1.22M 10-Q · filed 2023-08-14 | -$2.48M 10-Q · filed 2024-08-08 | -$2.48M 10-Q · filed 2023-08-14 | -$3.95M derived: sum of 3 quarters · filed 2024-08-08 | -$5.72M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | -$1.25M 10-Q · filed 2024-05-09 | -$2.73M derived: sum of 2 quarters · filed 2024-05-09 | -$4.50M derived: sum of 3 quarters · filed 2024-05-09 | -$6.43M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | -$1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$3.24M derived: sum of 2 quarters · filed 2024-03-14 | -$5.17M derived: sum of 3 quarters · filed 2024-03-14 | -$7.55M 10-K · filed 2024-03-14 | |||
| 2022-09-30 | -$1.77M 10-Q · filed 2023-11-13 | -$3.70M derived: sum of 2 quarters · filed 2023-11-13 | -$6.08M 10-Q · filed 2023-11-13 | ||||
| 2022-06-30 | -$1.93M 10-Q · filed 2023-08-14 | -$4.31M 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |